CRWD
CrowdStrike Holdings, Inc.
CRWD has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CRWD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Strong | |
| Unavailable |
CRWD's revenue and cash flow are currently healthy, and its profitability is stable. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CRWD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 153x | $230 | — |
| Cheap | 451x | $27.04 | -88% |
| Fair | 715x | $42.92 | -81% |
| Expensive | 3,337x | $200 | -13% |
| Current | 3,678x | $230 | — |
Historical ranges are pointers, not guarantees.
CRWD's PE is in its expensive range at 3678x. If earnings grow as analysts expect, today's price would be 153x next year's earnings, in its cheap range.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over CRWD in the historical PE scenario, which offers more potential upside but is not a forecast.
CRWD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Broad | |
| High |
CRWD has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CRWD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.50 | +2400% |
| Q3 2026 | $0.06 | +$0.36 |
| Q2 2026 | -$0.03 | +$0.14 |
| Q1 2026 | -$0.16 | -$0.14 |
| Q4 2025 | -$0.32 | -346% |
| Q3 2025 | -$0.30 | -276% |
| Q2 2025 | -$0.17 | -221% |
| Q1 2025 | -$0.02 | -122% |
| Q4 2024 | $0.13 | +$0.15 |
CRWD has returned to profit: it earned $0.06 per share over the past year, after losing money the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CRWD on earnings, with more consistent year-over-year improvement.
CRWD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +26% |
| Q2 2026 | $1.4B | +26% |
| Q1 2026 | $1.3B | +23% |
| Q4 2025 | $1.2B | +22% |
| Q3 2025 | $1.2B | +21% |
| Q2 2025 | $1.1B | +20% |
| Q1 2025 | $1.1B | +25% |
| Q4 2024 | $1B | +29% |
CRWD has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.3% | +7.4 points |
| Q2 2026 | -2.2% | +9.1 points |
| Q1 2026 | 1.1% | +9.1 points |
| Q4 2025 | -5.6% | -0.1 points |
| Q3 2025 | -9.7% | -11 points |
| Q2 2025 | -11% | -12 points |
| Q1 2025 | -8.1% | -12 points |
| Q4 2024 | -5.5% | -5.9 points |
CRWD's operating margin was −2.3% last quarter, up 7.4 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CRWD on profitability, with a higher operating margin.
CRWD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $405.9M | +34% |
| Q2 2026 | $493.3M | +65% |
| Q1 2026 | $395.4M | +53% |
| Q4 2025 | $314.1M | +27% |
| Q3 2025 | $302.3M | +5.2% |
| Q2 2025 | $298.4M | -11% |
| Q1 2025 | $258.5M | -12% |
| Q4 2024 | $247.4M | -1.9% |
CRWD's free cash flow has been positive every quarter for seven years: $1.6B over the past year, up 45% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
CRWD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +12.9M shares |
| 1 year | +4.5% | +44.8M shares |
| 3 years | +7.8% | +75.9M shares |
| 5 years | +15% | +139M shares |
| Available history | +28% | +228M shares |
CRWD has 1B diluted shares, up 4.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $175.6M |
| Q1 2020 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CRWD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CRWD Net Leverage
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CRWD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.1 | Neutral |
| Stochastic | 49.1 | Neutral |
CRWD's weekly RSI is 55 (neutral) and its Stochastic is 49 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CRWD PE vs Technology Sector
| Metric | CRWD | Sector median | Relative |
|---|---|---|---|
| PE | 3,678x | 28x | 13,101% above |
| PE % | 91 | 35 | 56 pts above |
CRWD is trading at 3678x earnings, a 13101% premium to the Technology sector's median of 28x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over CRWD on valuation relative to its sector.
CRWD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $247.4 | 7.1% below |
| 20 week MA | $221.9 | 3.6% above |
| 50 week MA | $163.0 | 41% above |
| 100 week MA | $136.0 | 69% above |
| 200 week MA | $97.5 | 136% above |
CRWD has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
CRWD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.2 | $55.3 | +352% |
| 2021 | $55.3 | $52.9 | -4.3% |
| 2022 | $52.9 | $25.5 | -52% |
| 2023 | $25.5 | $63.8 | +150% |
| 2024 | $63.8 | $88.8 | +39% |
| 2025 | $88.8 | $120.3 | +36% |
| 2026 YTD | $120.3 | $229.9 | +91% |
CRWD has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.